These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 2398363)

  • 1. Immunity of fetal mice to prenatal administration of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Melamed E; Rosenthal J; Youdim MB
    J Neurochem; 1990 Oct; 55(4):1427-31. PubMed ID: 2398363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different susceptibility to 1-methyl-4-phenylpyridium (MPP(+))-induced nigro-striatal dopaminergic cell loss between C57BL/6 and BALB/c mice is not related to the difference of monoamine oxidase-B (MAO-B).
    Ito T; Suzuki K; Uchida K; Nakayama H
    Exp Toxicol Pathol; 2013 Jan; 65(1-2):153-8. PubMed ID: 21855308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D; Samantaray S; Mohanakumar KP
    Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevation of neuronal MAO-B activity in a transgenic mouse model does not increase sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Andersen JK; Frim DM; Isacson O; Beal MF; Breakefield XO
    Brain Res; 1994 Sep; 656(1):108-14. PubMed ID: 7804823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of L-deprenyl treatment, alone and combined with GM1 ganglioside, on striatal dopamine content and substantia nigra pars compacta neurons.
    Rothblat DS; Schneider JS
    Brain Res; 1998 Jan; 779(1-2):226-30. PubMed ID: 9473679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity.
    Zuddas A; Fascetti F; Corsini GU; Piccardi MP
    Exp Neurol; 1994 May; 127(1):54-61. PubMed ID: 8200437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.
    Przedborski S; Kostic V; Jackson-Lewis V; Naini AB; Simonetti S; Fahn S; Carlson E; Epstein CJ; Cadet JL
    J Neurosci; 1992 May; 12(5):1658-67. PubMed ID: 1578260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment.
    Irwin I; Finnegan KT; Delanney LE; Di Monte D; Langston JW
    Brain Res; 1992 Feb; 572(1-2):224-31. PubMed ID: 1611516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra.
    Ricaurte GA; Irwin I; Forno LS; DeLanney LE; Langston E; Langston JW
    Brain Res; 1987 Feb; 403(1):43-51. PubMed ID: 3493827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B.
    Finnegan KT; Irwin I; Delanney LE; Langston JW
    J Pharmacol Exp Ther; 1995 May; 273(2):716-20. PubMed ID: 7752075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss.
    Grünblatt E; Mandel S; Maor G; Youdim MB
    J Neurochem; 2001 Apr; 77(1):146-56. PubMed ID: 11279270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions.
    Fornai F; Alessandrì MG; Torracca MT; Bassi L; Corsini GU
    J Pharmacol Exp Ther; 1997 Oct; 283(1):100-7. PubMed ID: 9336313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Youngster SK; Sonsalla PK; Heikkila RE
    J Neurochem; 1987 Mar; 48(3):929-34. PubMed ID: 3492590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs with potent nigrostriatal toxicity for potential use in positron emission tomography studies.
    Harik SI; Riachi NJ; Hritz MA; Berridge MS; Sayre LM
    J Pharmacol Exp Ther; 1993 Aug; 266(2):790-5. PubMed ID: 8355208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B.
    Quinn LP; Crook B; Hows ME; Vidgeon-Hart M; Chapman H; Upton N; Medhurst AD; Virley DJ
    Br J Pharmacol; 2008 May; 154(1):226-33. PubMed ID: 18332857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor.
    Sagi Y; Weinstock M; Youdim MB
    J Neurochem; 2003 Jul; 86(2):290-7. PubMed ID: 12871570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
    Muthian G; Mackey V; King J; Charlton CG
    Neuroscience; 2010 Sep; 169(3):1085-93. PubMed ID: 20540993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2'Me-MPTP.
    Kindt MV; Youngster SK; Sonsalla PK; Duvoisin RC; Heikkila RE
    Eur J Pharmacol; 1988 Feb; 146(2-3):313-8. PubMed ID: 3131149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MPTP toxicity in relation to age, dopamine uptake and MAO-B activity in two rodent species.
    Jossan SS; Sakurai E; Oreland L
    Pharmacol Toxicol; 1989 Mar; 64(3):314-8. PubMed ID: 2786198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of dopaminergic toxicity of MPTP in mice by phenylethylamine, a specific substrate of type B monoamine oxidase.
    Melamed E; Youdim MB
    Br J Pharmacol; 1985 Nov; 86(3):529-31. PubMed ID: 3877535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.